Lyra Therapeutics, Inc. (LYRA)
Automate Your Wheel Strategy on LYRA
With Tiblio's Option Bot, you can configure your own wheel strategy including LYRA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LYRA
- Rev/Share 0.901
- Book/Share 2.9441
- PB 3.6276
- Debt/Equity 8.6147
- CurrentRatio 2.956
- ROIC -1.6642
- MktCap 14154631.0
- FreeCF/Share -43.0267
- PFCF -0.2501
- PE -0.1766
- Debt/Assets 0.5923
- DivYield 0
- ROE -4.7437
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why
Published: June 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Lyra Therapeutics (LYRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive
LYRA skyrockets 356% after its lead nasal implant, LYR-210, meets key goals in a pivotal phase III chronic rhinosinusitis study.
Read More
This penny stock just spiked 550% in a day; Time to buy?
Published: June 02, 2025 by: Finbold
Sentiment: Positive
Lyra Therapeutics (NASDAQ: LYRA) ‘s shares surged 550% in pre-market trading on Monday following a breakthrough in its drug trials.
Read More
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today announced positive results from the ENLIGHTEN 2 Phase 3 clinical trial of LYR-210 in adult patients with CRS. The ENLIGHTEN 2 trial met its primary endpoint, with LYR-210 demonstrating statistically significant improvement compared to sham control in a composite of the three cardinal symptoms (3CS) of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at week 24 (-1.13; p=0.0078) in patients without nasal polyps.
Read More
Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today announced that the Company plans to present results from the 52-week Extension Stage of the ENLIGHTEN 1 Phase 3 study for LYR-210, the Company's lead product candidate for CRS, at the annual Combined Otolaryngology Spring Meetings (COSM 2025) being held May 14-18 in New Orleans.
Read More
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.35 per share a year ago.
Read More
About Lyra Therapeutics, Inc. (LYRA)
- IPO Date 2020-05-01
- Website https://lyratherapeutics.com
- Industry Biotechnology
- CEO Dr. Maria Palasis Ph.D.
- Employees 30